Sol-Gel Technologies Ltd. (SLGL): Price and Financial Metrics


Sol-Gel Technologies Ltd. (SLGL): $10.34

0.29 (+2.89%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SLGL POWR Grades


  • Sentiment is the dimension where SLGL ranks best; there it ranks ahead of 96.2% of US stocks.
  • SLGL's strongest trending metric is Momentum; it's been moving down over the last 206 days.
  • SLGL's current lowest rank is in the Momentum metric (where it is better than 11.51% of US stocks).

SLGL Stock Summary

  • The ratio of debt to operating expenses for Sol-Gel Technologies Ltd is higher than it is for about merely 8.65% of US stocks.
  • With a price/sales ratio of 30.03, Sol-Gel Technologies Ltd has a higher such ratio than 93.03% of stocks in our set.
  • Revenue growth over the past 12 months for Sol-Gel Technologies Ltd comes in at -61.7%, a number that bests only 4.82% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sol-Gel Technologies Ltd are SEAC, SRTS, INTZ, UTSI, and KMDA.
  • SLGL's SEC filings can be seen here. And to visit Sol-Gel Technologies Ltd's official web site, go to www.sol-gel.com.

SLGL Price Target

For more insight on analysts targets of SLGL, see our SLGL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.00 Average Broker Recommendation 1.25 (Strong Buy)

SLGL Stock Price Chart Interactive Chart >

Price chart for SLGL

SLGL Price/Volume Stats

Current price $10.34 52-week high $16.69
Prev. close $10.05 52-week low $7.00
Day low $10.05 Volume 7,096
Day high $10.41 Avg. volume 57,781
50-day MA $12.03 Dividend yield N/A
200-day MA $9.53 Market Cap 210.83M

Sol-Gel Technologies Ltd. (SLGL) Company Bio


Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea; and TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris. It is also involved in the development of generic dermatological candidates; and formulation and pre-clinical development of early stage product candidates for acne and rosacea, and other dermatological indications. The company was founded in 1997 and is based in Ness Ziona, Israel


SLGL Latest News Stream


Event/Time News Detail
Loading, please wait...

SLGL Latest Social Stream


Loading social stream, please wait...

View Full SLGL Social Stream

Latest SLGL News From Around the Web

Below are the latest news stories about Sol-Gel Technologies Ltd that investors may wish to consider to help them evaluate SLGL as an investment opportunity.

Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update

- Sol-Gel is in advanced negotiations with a potential partner regarding the commercialization of EPSOLAY® and TWYNEO® - EPSOLAY PDUFA goal date was set for April 26, 2021. Awaiting FDA’s pre-approval inspection - TWYNEO PDUFA goal date set for August 1, 2021 NESS ZIONA, Israel, May 13, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stagedermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial results for the first quarter ended March 31, 2021 and provided corporate updates. Corporate Highlights and Recent Developments Sol-Gel is in advanced negotiations with a potential partner regarding the commercialization of EPSOLAY (benzoyl perox...

Yahoo | May 13, 2021

Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates

Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May. ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD ) Nuplazid failed to get label expansion to include the indication of dementia-related psychosis. The FDA did not keep its tryst with the decision dates for ACADIA Pharmaceuticals Inc.'s (NASDAQ: ACAD ) pain drug and Sol-Gel Technologies Ltd.'s (NASDAQ: SLGL ) investigational skin inflammation treatment. Protalix BioTherapeutics, Inc.'s (NASDAQ: PLX ) Fabry disease treatment candidate also faced rejection at the FDA altar. The regulatory agency extended the review period for Pfizer Inc.'s (NYSE: PFE ) atopic dermatitis drug. On the other hand, Supernus Pharmaceuticals, Inc.'s (NASDAQ: SUPN ) attention deficit hyperactivity drug ...

Benzinga | May 1, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sol-Gel Technologies Ltd. - SLGL

NEW YORK , April 28, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sol-Gel Technologies Ltd. ("Sol-Gel" or the "Company") (NASDAQ: SLGL ) Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. … Full story available on Benzinga.com

Benzinga | April 28, 2021

Sol-Gel says no FDA notification regarding its marketing application for EPSOLAY

Sol-Gel Technologies ([[SLGL]] -21.1%) has shed more than a fifth in value after announcing that the company received no notification from the FDA regarding its marketing application for EPSOLAY (benzoyl peroxide) 5% topical cream for adults with Inflammatory lesions of rosacea.However, Sol-Gel says it received an email confirmation from the regulator...

Seeking Alpha | April 27, 2021

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

Cyclerion Therapeutics, Inc. (NASDAQ: CYCN ), Sol-Gel Technologies Ltd. (NASDAQ: SLGL ), Aldeyra Therapeutics, Inc. (NASDAQ: ALDX ), DermTech, Inc. (NASDAQ: DMTK ) and Bionano Genomics, Inc. (NASDAQ: BNGO ) are among the biggest health care movers Tuesday. Cyclerion Slips On Study Delay: Cyclerion, a clinical-stage biopharma developing treatments for restoring cognitive functions, provided a clinical pipeline update. The company delved on the development strategy and execution for its lead asset CY6463, which is being evaluated in Alzheimer's disease with vascular pathology as well as mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes, or MELAS. The MELAS study is enrolling more slowly than initially projected, primarily due to COVID-19, the company said. It now ex...

Benzinga | April 27, 2021

Read More 'SLGL' Stories Here

SLGL Price Returns

1-mo -27.99%
3-mo 2.17%
6-mo 28.61%
1-year 26.10%
3-year 11.54%
5-year N/A
YTD 5.62%
2020 -42.92%
2019 184.88%
2018 N/A
2017 N/A
2016 N/A

Continue Researching SLGL

Want to see what other sources are saying about Sol-Gel Technologies Ltd's financials and stock price? Try the links below:

Sol-Gel Technologies Ltd (SLGL) Stock Price | Nasdaq
Sol-Gel Technologies Ltd (SLGL) Stock Quote, History and News - Yahoo Finance
Sol-Gel Technologies Ltd (SLGL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8425 seconds.